Published in Nat Sci Sleep on September 08, 2010
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med (2003) 12.71
A genetic risk factor for periodic limb movements in sleep. N Engl J Med (2007) 5.77
Restless legs syndrome. Neurology (1960) 5.38
Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med (2005) 4.97
Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med (2003) 4.95
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med (2004) 3.49
Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord (1997) 2.67
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology (2002) 2.53
Sex and the risk of restless legs syndrome in the general population. Arch Intern Med (2004) 2.43
Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology (2000) 2.34
Clinical practice. Restless legs syndrome. N Engl J Med (2003) 2.10
Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study. Pediatrics (2007) 2.07
Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology (2003) 2.04
Therapy in restless legs. Acta Med Scand (1953) 2.00
The PAM-RL ambulatory device for detection of periodic leg movements: a validation study. Sleep Med (2005) 1.96
Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med (2009) 1.95
Iron status and restless legs syndrome in the elderly. Age Ageing (1994) 1.87
Iron and the restless legs syndrome. Sleep (1998) 1.87
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med (2009) 1.80
Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med (2004) 1.79
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet (2008) 1.78
Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology (2005) 1.77
Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology (2000) 1.75
MRI measurement of brain iron in patients with restless legs syndrome. Neurology (2001) 1.75
An algorithm for the management of restless legs syndrome. Mayo Clin Proc (2004) 1.67
Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med (2005) 1.60
Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharmacol Biochem Behav (2001) 1.59
Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med (2006) 1.58
Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) (1984) 1.56
Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain (2009) 1.53
Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol (2001) 1.53
Diagnosis and management of restless legs syndrome in children. Sleep Med Rev (2009) 1.49
Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med (2008) 1.48
Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med (2010) 1.48
Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci (2008) 1.46
Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology (1999) 1.46
CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res (2005) 1.46
Treatment of the restless legs syndrome with clonazepam. Br Med J (1979) 1.44
Evaluating the quality of life of patients with restless legs syndrome. Clin Ther (2004) 1.44
Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology (2007) 1.42
Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology (2005) 1.39
Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand (1984) 1.38
Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep (2000) 1.37
Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep (2005) 1.34
An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep (2004) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet (2001) 1.30
Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain (2003) 1.29
Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med (2003) 1.27
Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med (2005) 1.26
Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics (2003) 1.26
Periodic leg movements in sleep in essential hypertension. Psychiatry Clin Neurosci (1997) 1.24
SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol (2002) 1.24
Restless legs syndrome in an Asian population: A study in Singapore. Mov Disord (2001) 1.24
Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep (1996) 1.23
Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med (2007) 1.23
Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord (1998) 1.22
Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol (2005) 1.22
An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology (2000) 1.22
MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet (2009) 1.21
A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology (1996) 1.21
Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med (2008) 1.20
Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet (2004) 1.18
Validation of the Johns Hopkins restless legs severity scale. Sleep Med (2001) 1.18
The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep (1999) 1.17
The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med (2004) 1.14
Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep (2008) 1.13
Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs (2004) 1.12
Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci (1994) 1.12
Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol (2006) 1.11
Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology (2003) 1.10
Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health (2005) 1.08
Why do restless legs occur at rest?--pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin Neurophysiol (2004) 1.05
Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs (2010) 1.05
A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord (2009) 1.05
Restless legs syndrome: a clinical update. Chest (2006) 1.04
Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet (2006) 1.03
Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specifically associated with sleep disorders involving a dopaminergic impairment. Sleep Med (2000) 1.03
Mechanism of oxygen activation by tyrosine hydroxylase. Biochemistry (1987) 1.02
Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep (1993) 1.00
Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation. Qual Life Res (2004) 1.00
Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev (2010) 0.99
A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med (2008) 0.99
Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med (2000) 0.98
The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med (2009) 0.97
A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology (2006) 0.97
Correlation between rating scales and sleep laboratory measurements in restless legs syndrome. Sleep Med (2004) 0.97
Mitochondrial ferritin in the substantia nigra in restless legs syndrome. J Neuropathol Exp Neurol (2009) 0.97
Restless legs syndrome: pathophysiology, diagnosis and treatment. CNS Drugs (2008) 0.97
Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord (2001) 0.97
Predisposing factors of restless legs syndrome in pregnancy. Mov Disord (2007) 0.95
Restless legs syndrome augmentation and pramipexole treatment. Sleep Med (2002) 0.95
Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail (2004) 0.95
Restless Legs Syndrome in patients after renal transplantation. Am J Kidney Dis (2005) 0.94
Restless legs syndrome in Parkinson's disease. Mov Disord (2007) 0.94
Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med (2005) 0.93
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet (2009) 3.18
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
A marker for the end of adolescence. Curr Biol (2004) 3.12
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Common variants in the JAZF1 gene associated with height identified by linkage and genome-wide association analysis. Hum Mol Genet (2008) 2.66
Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet (2012) 2.34
A global in vivo Drosophila RNAi screen identifies NOT3 as a conserved regulator of heart function. Cell (2010) 2.27
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations. PLoS Genet (2012) 1.79
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis (2009) 1.78
Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet (2009) 1.77
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Linkage disequilibrium patterns and tagSNP transferability among European populations. Am J Hum Genet (2005) 1.72
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet (2012) 1.68
Genome-wide association analysis identifies multiple loci related to resting heart rate. Hum Mol Genet (2010) 1.67
The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord (2014) 1.64
The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives. BMC Med Genet (2007) 1.64
Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One (2011) 1.62
Genes predict village of origin in rural Europe. Eur J Hum Genet (2010) 1.61
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int (2009) 1.48
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
Exclusion of linkage to chromosome 14q in a large South Tyrolean family with Idiopathic Basal Ganglia Calcification (IBGC). Am J Med Genet B Neuropsychiatr Genet (2008) 1.42
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
A genome-wide association scan of RR and QT interval duration in 3 European genetically isolated populations: the EUROSPAN project. Circ Cardiovasc Genet (2009) 1.35
Localising loci underlying complex trait variation using Regional Genomic Relationship Mapping. PLoS One (2012) 1.34
Discovery and fine mapping of serum protein loci through transethnic meta-analysis. Am J Hum Genet (2012) 1.29